Other
Journal
About P&T Journal
Contacts:Editor:
ssherritze@medimedia.com
Advertising:
mliberti@medimedia.com
Circulation:
lgardineer@medimedia.com
Production:
wpeart@medimedia.com
Rate Card
Production Specifications
Statement of Purpose
Guidelines for Authors
Masthead
Editorial Board
Reprints
Recent Issues
August 2009
Features
Commentary
Will Pharma Twitter?
In addition to blogging and featuring their own Web sites, some drug companies are cautiously entering the Twitter community as they seek additional outlets for reaching their audience.
Miriam Reisman
Warfarin Pharmacogenomics
Warfarin is commonly used to prevent and treat thromboembolic disease, but it is difficult to administer at the correct dose, primarily because of variations in patient responses. With new advances in medicine, it may be possible to tailor pharmacotherapy based on a patient’s genetic profile.
Jiayi Li, MD; Shan Wang, PharmD, RPh; Joseph Barone, PharmD Candidate; and Brian Malone, MS, RPh
FDA Policy
Off-Label Drug Information
Regulation, Distribution, Evaluation, and Related Controversies
Although one of the FDA’s main goals is to protect consumers from unsafe products, the off-label use of prescription drugs is quite common. The history and debate regarding the distribution of off-label drug information and the FDA’s inability to limit non-approved uses of pharmaceuticals are reviewed.
C. Lee Ventola, MS
Meeting Highlights
Medical Design and Manufacturing East Conference and Exhibition 2009
This conference covered requirements for FDA approval of medical devices, including classifications, premarket submissions, and 510(k) reviews. Investigational devices and humanitarian use devices are also presented.
Marvin M. Goldenberg, PhD, RPh, MS
Meeting Highlights
American Diabetes Association and European League Against Rheumatism
Some of the topics covered at the ADA sessions included therapies for achieving glycemic control in patients with type-2 diabetes. The EULAR meeting featured discussions of agents such as abatacept (Orencia) and tumor necrosis factor inhibitors for rheumatoid arthritis.
Walter Alexander
Departments
Editorial
The Public Plan: A ‘Straw Man’?
David B. Nash, MD, MBA, explains why he thinks the Obama administration’s proposed government-sponsored health insurance company might be just a political “straw man.”
David B. Nash, MD, MBA
Medication Errors
Preventing Magnesium Toxicity in Obstetrics
Matthew Grissinger, RPh, FASCP, presents the dangers of the improper use of magnesium sulfate in obstetrical practice.
Matthew Grissinger, RPh, FASCP
Prescription: Washington
Pharmacy Take-Back Programs
Opportunities for Congress, Liabilities for Pharmacies
Stephen Barlas describes new government rules that might force pharmacies to take back unused and expired prescription drugs, including controlled substances, for proper disposal.
Stephen Barlas
New Drugs/Drug News/New Medical Devices
From Alimta to Zyban, P&T presents the latest studies about FDA approvals, new indications, recalls, and industry updates.
Drug Forecast
Prasugrel (Effient), an Adenosine Diphosphate Receptor Antagonist for the Treatment of Acute Coronary Syndrome
Prasugrel (Effient), an antiplatelet agent, is now approved for patients with acute coronary syndrome.
Miren E. Jauregui, PharmD, Ogochukwu U. Umejei, PharmD, and Martin P. Cruz, PharmD, CGP, BCPP
